unknown
Stage
2020
Founded
4
Investors
About
Aktis Oncology develops targeted alpha-based radiopharmaceuticals using a proprietary miniprotein radioconjugate platform to treat a broad range of solid tumor cancers with significant unmet medical needs.
Explore Aktis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.